EIAab
Home > Citations> Asprosin in pregnancy and childhood
Asprosin in pregnancy and childhood

Introduction

The prevalence for childhood overweight and obesity increased steadily in the past decades. Childhood obesity was defined as a disease by the World Health Organization [25] and by the American Medical Association (2013) [7] and is listed in the International Statistical Classification of Diseases and Related Health Problems in (ICD). In 2016 over 340 million children and adolescents, aged 5–19 were overweight or obese and current estimates suggest approximately 38 million children under the age of 5 as overweight or obese [25]. Amongst genetic factors and environmental influences, a variety of perinatal risk factors individually or in combination contributes to the development of infant obesity. Especially maternal pre-pregnancy obesity, excessive gestational weight gain and gestational diabetes result in pathological pregnancy conditions. Insulin resistance (IR), elevated blood glucose levels and hormonal disturbance provoke the malprogramming of infant’s energy metabolism [11].


Cited products
Source:Molecular and Cellular Pediatrics     by R Janoschek, T Hoffmann, G Sengle, et al.
用户中心 close
购物车 close
我的收藏 close
我的足迹 close
清除
产品对比 close
用户中心
购物车
我的收藏
我的足迹
产品对比
回到顶部
通知
new 咨询
规格 数量 单价 (¥) 小计 1 (¥)
小计 2:
triangle
规格 数量 单价 (¥)
你想做我们的代理并得到更低的折扣吗?
请联系我们:
电话:027-59234612(+86)
传真:027-59234610(+86)
邮箱:sales@eiaab.com